Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (1672)	2/1/2001 7:16:26 PM
From: software salesperson	Read Replies (2) \| Respond to of 3202

2/1/01 conference call notes 1. year 2000 review (i) direct sales force global expansion (ii) selling access to data via internet (iii) sankyo,sumitomo,corning,agilent,sqnm,motorola,perkin-elmer,oxagen deals; 5 academic alliances (iv) has over 1000 scientists involved in incy-proprietary research through deals and internal efforts 2. 2001 objectives (i) “ catalyze our internal disease pathway discovery and therapeutic drug research programs”- - say what?? , i.e. more aggressively focus on leveraging their proprietary data in target discovery/ validation and disease markers through a greater number of alliances; specifically mentioned a deal with an antibody company (ii) a few partners have told them to expect that they may be entering clinical trials in 2001, triggering royalty payments (iii) approx. 20% top-line growth (iv) possible pharma deal (v) begin selling proteome’s data 3. q & a (i) expects breakeven for 2001 (ii) optimistic that they will probably file for summary judgment in affx case(end 2001 earliest), though at another point, seemed to be talking like they’d settle 4. impressions - - a very skeptical analyst community who still does not buy into the model sales